Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing AbbVie Inc.'s Androgel® Topical Gel, 1.62% packets (20.25 mg/1.25 g packet and 40.5 mg/2.5 g packet).
Androgel® Topical Gel, 1.62% packets is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. Annual market sales for Androgel® Topical Gel, 1.62% packets for the 12 months ending May 2017 were approximately $88 million.
Perrigo Executive Vice President and President Rx Pharmaceuticals John Wesolowski stated, "This final approval is another example of our long-term investment in new products. The Rx team remains committed to providing affordable treatments options for patients in important extended topical categories."
Source
Androgel® Topical Gel, 1.62% packets is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. Annual market sales for Androgel® Topical Gel, 1.62% packets for the 12 months ending May 2017 were approximately $88 million.
Perrigo Executive Vice President and President Rx Pharmaceuticals John Wesolowski stated, "This final approval is another example of our long-term investment in new products. The Rx team remains committed to providing affordable treatments options for patients in important extended topical categories."
Source
